Cargando…

Targeted pharmacotherapy after somatic cancer mutation screening

Many patients with solid tumours are treated with targeted pharmacotherapy based on the results of genetic testing (‘precision medicine’). This study investigated the use of targeted drugs after OncoFOCUS™+ KIT screening in patients with malignant melanoma, non-small cell lung cancer and metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Polasek, Thomas M., Ambler, Karen, Scott, Hamish S., Sorich, Michael J., Kaub, Peter A., Rowland, Andrew, Wiese, Michael D., Kichenadasse, Ganessan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000Research 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5247780/ https://www.ncbi.nlm.nih.gov/pubmed/28163892 http://dx.doi.org/10.12688/f1000research.9040.2

Ejemplares similares

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study
por: Mangoni, Arduino A., et al.
Publicado: (2018)

Nuances to precision dosing strategies of targeted cancer medicines
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data
por: Sorich, Michael J, et al.
Publicado: (2016)

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
por: Hopkins, Ashley M, et al.
Publicado: (2017)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
por: Hopkins, Ashley M., et al.
Publicado: (2021)

The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data
por: Modi, Natansh D., et al.
Publicado: (2020)

Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
por: Hopkins, Ashley M, et al.
Publicado: (2023)

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
por: Modi, Natansh D., et al.
Publicado: (2021)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages
por: Hopkins, Ashley M., et al.
Publicado: (2023)

Radiation Induced Leiomyosarcoma Three Decades After Treatment for Wilms’ Tumor
por: Khattak, Muhammad A, et al.
Publicado: (2010)

ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study
por: Lemech, Charlotte Rose, et al.
Publicado: (2022)

Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report
por: Abbas, M. Nazim, et al.
Publicado: (2021)

A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies
por: Modi, Natansh D., et al.
Publicado: (2023)

Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability
por: Hopkins, Ashley M., et al.
Publicado: (2018)

Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease
por: Newman, Lauren A., et al.
Publicado: (2020)

Protocol for the Flinders Kidney Health Registry: patient outcomes of kidney cancers and nephrectomies
por: Li, Jordan Y., et al.
Publicado: (2022)

Evaluation of selective bone scan staging in prostate cancer – external validation of current strategies and decision-curve analysis
por: Hiwase, Mrunal D., et al.
Publicado: (2022)

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil
por: Rowland, Angela, et al.
Publicado: (2016)

Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing
por: Ruanglertboon, Warit, et al.
Publicado: (2021)

Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges
por: van Leuven, Jason, et al.
Publicado: (2023)

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

The emergence of extracellular vesicles in urology: fertility, cancer, biomarkers and targeted pharmacotherapy
por: Tompkins, Andrew J., et al.
Publicado: (2015)

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
por: Blinman, Prunella, et al.
Publicado: (2013)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
por: Hopkins, Ashley M., et al.
Publicado: (2019)

Eprobe-mediated screening system for somatic mutations in the KRAS locus
por: ATSUMI, JUN, et al.
Publicado: (2015)

Somatic mutations in salivary duct carcinoma and potential therapeutic targets
por: Khoo, Timothy K., et al.
Publicado: (2017)

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials
por: Hopkins, Ashley M., et al.
Publicado: (2018)

Pharmacotherapy for Irritable Bowel Syndrome
por: Camilleri, Michael, et al.
Publicado: (2017)

Novel Pharmacotherapies in Parkinson’s Disease
por: Tizabi, Yousef, et al.
Publicado: (2021)

Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020
por: Obermair, Andreas, et al.
Publicado: (2021)

COSMIC: the catalogue of somatic mutations in cancer
por: Bindal, Nidhi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_s1704gu3mphqhjkf730l5fi33o